Prevalence of insomnia: a survey of the enrollees at five managed care organizations.
Prevalence of insomnia: a survey of the enrollees at five managed care organizations.
复制标题
失眠症患病率：对五个管理式医疗组织的参与者进行的调查。
DOI：
--
复制
发表时间：
1998
影响因子：
3.2
通讯作者：
Mendelson Wb
中科院分区：
文献类型：
--
作者：
Hind T. Hatoum;Kania Cm;S. X. Kong;Wong Jm;Mendelson Wb
该研究的目的是评估失眠的患病率和相关因素之间的管理式护理组织（MCO）的注册者。通过邮件或在诊所访问期间向美国五个MCO的7，500名注册者分发了一份调查。该调查包括睡眠问卷，人口统计学问题，以及有关医疗接触和处方药使用的问题。从回答中定义了三个级别的失眠（无; I级-难以启动或维持睡眠; II级-失眠伴日间功能障碍）。根据受访者报告的处方药使用情况，由代理人确定合并症。共收到3，447份调查回复，回复率为46%。I级和II级失眠分别占13.5%和32.5%。II级失眠随着教育程度、收入和年龄的降低而增加，在女性和非白人中更为普遍。失眠与所有白天嗜睡和大多数夜间干扰因素显著相关。52%的受访者报告至少有一种共病。有多种合并症的受访者比没有合并症的受访者更频繁地报告II级失眠。只有0.9%的诊所访客专门为睡眠问题看医生。在I级和II级失眠症患者中，分别只有5.5%和11.6%的人服用了专门针对睡眠问题的处方药;分别有11.2%和21.4%的人服用了非处方药。MCO入组者中的胰岛素抵抗发生率与一般人群中的胰岛素抵抗发生率相当。然而，很少有失眠患者真正接受治疗。正确的评估，诊断和治疗失眠是必要的。
The purpose of the study was to assess the prevalence of and factors associated with insomnia among enrollees of managed care organizations (MCOs). A survey was distributed either by mail or during a clinic visit to 7,500 enrollees of five MCOs in the United States. The survey included a sleep questionnaire, demographic questions, and questions about medical encounters and prescription drug use. Three levels of insomnia (none; level I--difficulty initiating or maintaining sleep; level II--insomnia with daytime dysfunction) were defined from the responses. Comorbidities were determined by proxy from prescription drug use reported by respondents. A total of 3,447 survey responses were received, yielding a response rate of 46%. Level I and level II insomnia was reported by 13.5% and 32.5% of the respondents, respectively. Level II insomnia increased with decreasing education, income, and age and was more prevalent in women and non-Caucasians. Insomnia was significantly correlated with all daytime sleepiness and most nighttime disturbances factors. Fifty-two percent of all respondents reported at least one comorbid condition. Respondents with multiple comorbidities reported level II insomnia more frequently than those with no comorbidities. Only 0.9% of clinic visitors were seeing a physician specifically for sleep problems. Of those with level I and level II insomnia, only 5.5% and 11.6%, respectively, were taking prescription medications specifically for sleep problems; 11.2% and 21.4%, respectively, were taking over-the-counter medications for sleep. Insomnia occurs in MCO enrollees at rates comparable to those found in the general population. However, few patients with insomnia are actually being treated for their condition. Proper evaluation, diagnosis, and treatment of insomnia are warranted.